103 related articles for article (PubMed ID: 29479067)
21. Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.
Maffei R; Colaci E; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
Crit Rev Oncol Hematol; 2016 Jan; 97():291-302. PubMed ID: 26454471
[TBL] [Abstract][Full Text] [Related]
22. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
[TBL] [Abstract][Full Text] [Related]
23. Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise.
Tam CS; Polliack A
Leuk Lymphoma; 2016; 57(6):1247-8. PubMed ID: 26732524
[No Abstract] [Full Text] [Related]
24. Management of patients with chronic lymphocytic leukemia treated with lenalidomide.
Miller KC; Musial L; Whitworth A; Chanan-Khan A
Clin J Oncol Nurs; 2010 Aug; 14(4):491-9. PubMed ID: 20682505
[TBL] [Abstract][Full Text] [Related]
25. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Chanan-Khan A; Miller KC; Lawrence D; Padmanabhan S; Miller A; Hernandez-Illatazurri F; Czuczman MS; Wallace PK; Zeldis JB; Lee K
Cancer; 2011 May; 117(10):2127-35. PubMed ID: 21523725
[TBL] [Abstract][Full Text] [Related]
26. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
27. Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia.
Zaja F; Russo D; Marin L; Silvestri F; Ramello M; Baccarani M
Ann Hematol; 1999 Sep; 78(9):435-6. PubMed ID: 10525833
[No Abstract] [Full Text] [Related]
28. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Arumainathan A; Kalakonda N; Pettitt AR
Eur J Haematol; 2011 Oct; 87(4):372-5. PubMed ID: 21679253
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I; Lund J; Gréen H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist UH; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Cancer Chemother Pharmacol; 2018 Jan; 81(1):183-193. PubMed ID: 29177954
[TBL] [Abstract][Full Text] [Related]
30. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
31. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide in CLL: what is the optimal dose?
Wendtner CM
Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
[No Abstract] [Full Text] [Related]
34. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
[TBL] [Abstract][Full Text] [Related]
35. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment.
Tosti S; Caruso R; D'Adamo F; Picardi A; Ali Ege M; Girelli G; Mauro FR; Maurillo L; Amadori S
Ann Hematol; 1992 Nov; 65(5):238-9. PubMed ID: 1457584
[No Abstract] [Full Text] [Related]
36. Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.
Fiorcari S; Martinelli S; Bulgarelli J; Audrito V; Zucchini P; Colaci E; Potenza L; Narni F; Luppi M; Deaglio S; Marasca R; Maffei R
Haematologica; 2015 Feb; 100(2):253-62. PubMed ID: 25398834
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
[TBL] [Abstract][Full Text] [Related]
38. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Wendtner CM; Hillmen P; Mahadevan D; Bühler A; Uharek L; Coutré S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
Leuk Lymphoma; 2012 Mar; 53(3):417-23. PubMed ID: 21879809
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
[TBL] [Abstract][Full Text] [Related]
40. Fever after cytotoxic therapy of chronic lymphocytic leukemia.
Zingman BS
Cancer Invest; 1999; 17(4):292-5. PubMed ID: 10225010
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]